Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Alveolar Soft Part Sarcoma: early-phase trial registry

3 of 5 indexed Alveolar Soft Part Sarcoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 3 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Alveolar Soft Part Sarcoma: 5 US clinical trials tracked, 3 recruiting.

Alveolar Soft Part Sarcoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 2 of these trials.

Enrollment posture brief

Registry condition alveolar-soft-part-sarcoma

OPEN 3 | RECR 60% | LATE 1 | EARLY 4 | RANK #3391 | SPON 2

Nearest open-share peer: Acute Kidney Injury (AKI) (60% recruiting · 5 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Alveolar Soft Part Sarco (th…60%
Open-enrollment share among volume-matched conditions near Alveolar Soft Part Sarcoma

Alveolar Soft Part Sarcoma lists 3 open slots (60% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Alveolar Soft Part Sarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Alveolar Soft Part Sarcoma is recruiting above its size-band peers.

    3 of 5 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Alveolar Soft Part Sarcoma research.

    National Cancer Institute (NCI) accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Typical Alveolar Soft Part Sarcoma enrolment sits around 109 participants.

    Median target enrolment is 109 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.

  4. Alveolar Soft Part Sarcoma research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 23Phase 31

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3
Phase 3 1

Named interventions

Most-linked intervention names on Alveolar Soft Part Sarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Pazopanib Hydrochloride Drug
1 trials
Pharmacological Study Other
1 trials
Digoxin (0.25mg) Drug
1 trials
Midazolam 2 mg for CYP3A4 phenotyping Drug
1 trials
AL3818 or placebo Drug
1 trials
AL3818 Drug
1 trials
infusion of melphalan and dactinomycin Drug
1 trials
Isolated Limb Infusion Procedure
1 trials

US sites by state

Facility locations filed on Alveolar Soft Part Sarcoma trials. A trial with sites in several states counts in each.

California 3 trials
New York 2 trials
Florida 2 trials
Colorado 2 trials
Arizona 2 trials
Arkansas 2 trials
Alabama 2 trials
Alaska 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Alveolar Soft Part Sarcoma page

5 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alveolar Soft Part Sarcoma condition card totals 5 registered trials; most-linked intervention Pazopanib Hydrochloride; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.